# Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response

> **NCT00392002** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2000 (—)

## Conditions studied

- Gastroesophageal Reflux

## Interventions

- **DRUG:** Esomeprazole

## Key facts

- **NCT ID:** NCT00392002
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** 2000 (—)
- **Last updated:** 2008-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00392002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00392002, "Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00392002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*